跳转至内容
Merck

SML2365

Sigma-Aldrich

Phenprocoumon

≥97% (HPLC)

别名:

2-Hydroxy-3-(1-phenylpropyl)-4H-1-benzopyran-4-one, 4-Hydroxy-3-(1-phenylpropyl)-2H-1-Benzopyran-2-one

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C18H16O3
CAS号:
分子量:
280.32
MDL號碼:
分類程式碼代碼:
12352200
NACRES:
NA.77

化驗

≥97% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 2 mg/mL, clear

儲存溫度

2-8°C

InChI

1S/C18H16O3/c1-2-13(12-8-4-3-5-9-12)16-17(19)14-10-6-7-11-15(14)21-18(16)20/h3-11,13,20H,2H2,1H3

InChI 密鑰

QNDUUBVQYBBRBW-UHFFFAOYSA-N

生化/生理作用

Phenprocoumon is a coumarin derivative that inhibits vitamin K and acts as a long acting oral anticoagulant. It was recently found to act synergistically with flutamide to modulate the stability of the androgen receptor (AR) and resensitize AR-mutant prostate cancer cells to flutamide.

象形圖

Skull and crossbonesHealth hazard

訊號詞

Danger

危險分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Repr. 2 - STOT RE 2

儲存類別代碼

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Eleanor Hüttel et al.
Thrombosis and haemostasis, 117(5), 870-879 (2017-02-24)
The aim of this observational cohort study was to specify the risk of the vitamin K antagonist (VKA) phenprocoumon during first trimester of pregnancy, in particular to estimate the risk of birth defects and spontaneous fetal loss. Four hundred eight
Marco P Licciardello et al.
Nature chemical biology, 13(7), 771-778 (2017-05-23)
Approved drugs are invaluable tools to study biochemical pathways, and further characterization of these compounds may lead to repurposing of single drugs or combinations. Here we describe a collection of 308 small molecules representing the diversity of structures and molecular
Stefan H Hohnloser et al.
Clinical research in cardiology : official journal of the German Cardiac Society, 106(8), 618-628 (2017-03-16)
Non-vitamin K antagonist oral anticoagulants (NOACs) are at least as effective and safe as vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF). All pivotal trials have compared NOACs to warfarin. However, other VKAs are commonly used, for

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门